Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

AIDS

Volumn 17, Issue 8, 2003, Pages 1258-1261

  Schnell, Tanja ^a   Schmidt, Barbara ^a   Moschik, Gitta ^a   Thein, Christine ^a   Paatz, Christiane ^a   Korn, Klaus ^a   Walter, Hauke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; LOPINAVIR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CROSS RESISTANCE; DRUG EFFICACY; EVALUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

CARBAMATES; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV; HIV PROTEASE INHIBITORS; HUMANS; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 0038543353     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00021     Document Type: Article

References (14)

1. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002; 288:222-235.
2. van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antiviral Ther 2001; 6:201-229.
3. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999; 13:2061-2068.
4. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-180.
5. Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Überla K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 1999; 13:71-80.
6. Means RE, Greenough T, Desrosiers RC. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol 1997; 69:5431-5436.
7. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44:2319-2326.
8. Colonno RJ, Friborg J, Rose RE, Lam E, Parkin N. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir-containing regimens. Antiviral Ther 2002; 7 (Suppl.):S4.
9. Haas DW, Zala C, Schrader S, Thiry A, McGovern R, Schnittman S. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial AI424-009, week 48). In: 9th Conference on Retroviruses and Opportunistic Infections. February 2002 [Abstract 42].
10. Schmidt B, Korn K, Moschik B, Paatz C, Uberla K, Walter H. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother 2000; 44:3213-3216.
11. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus neviraplne and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185:599-607.
12. Duval X, Lamotte C, Race E, Descamps D, Damond F, Clavel F, et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother 2002; 46:570-574.
13. Szumiloski J, Wilson H, Jensen E, Campo R, Miller N, Rice H, et al. Relationships between indinavir resistance and virological responses to indinavlr-ritonavir-containing regimens in patients with previous protease inhibitor failure. Antiviral Ther 2002; 7 (Suppl.):S127.
14. min levels for response to a ritonavir boosted saquinavir salvage therapy. Antiviral Ther 2002; 7 (Suppl.):S81.